Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Cancer statistics for African Americans, 2013.

DeSantis C, Naishadham D, Jemal A.

CA Cancer J Clin. 2013 May;63(3):151-66. doi: 10.3322/caac.21173. Epub 2013 Feb 5.

2.

Cancer statistics, 2013.

Siegel R, Naishadham D, Jemal A.

CA Cancer J Clin. 2013 Jan;63(1):11-30. doi: 10.3322/caac.21166. Epub 2013 Jan 17.

3.

The influence of sex, race/ethnicity, and educational attainment on human immunodeficiency virus death rates among adults, 1993-2007.

Simard EP, Fransua M, Naishadham D, Jemal A.

Arch Intern Med. 2012 Nov 12;172(20):1591-8.

PMID:
23045164
4.

Cancer statistics for Hispanics/Latinos, 2012.

Siegel R, Naishadham D, Jemal A.

CA Cancer J Clin. 2012 Sep-Oct;62(5):283-98. doi: 10.3322/caac.21153.

5.

Age-specific trends in black-white disparities in cervical cancer incidence in the United States: 1975-2009.

Simard EP, Naishadham D, Saslow D, Jemal A.

Gynecol Oncol. 2012 Dec;127(3):611-5. doi: 10.1016/j.ygyno.2012.08.021. Epub 2012 Aug 23.

PMID:
22922530
6.

Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C.

Morishima C, Shiffman ML, Dienstag JL, Lindsay KL, Szabo G, Everson GT, Lok AS, Di Bisceglie AM, Ghany MG, Naishadham D, Morgan TR, Wright EC; HALT-C Trial Group.

Am J Gastroenterol. 2012 Sep;107(9):1388-98. doi: 10.1038/ajg.2012.137. Epub 2012 Jun 12.

7.

Cancer statistics, 2012.

Siegel R, Naishadham D, Jemal A.

CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. doi: 10.3322/caac.20138. Epub 2012 Jan 4.

8.

Predicting US- and state-level cancer counts for the current calendar year: Part II: evaluation of spatiotemporal projection methods for incidence.

Zhu L, Pickle LW, Ghosh K, Naishadham D, Portier K, Chen HS, Kim HJ, Zou Z, Cucinelli J, Kohler B, Edwards BK, King J, Feuer EJ, Jemal A.

Cancer. 2012 Feb 15;118(4):1100-9. doi: 10.1002/cncr.27405. Epub 2012 Jan 6.

9.

Predicting US- and state-level cancer counts for the current calendar year: Part I: evaluation of temporal projection methods for mortality.

Chen HS, Portier K, Ghosh K, Naishadham D, Kim HJ, Zhu L, Pickle LW, Krapcho M, Scoppa S, Jemal A, Feuer EJ.

Cancer. 2012 Feb 15;118(4):1091-9. doi: 10.1002/cncr.27404. Epub 2012 Jan 6.

10.

State disparities in colorectal cancer mortality patterns in the United States.

Naishadham D, Lansdorp-Vogelaar I, Siegel R, Cokkinides V, Jemal A.

Cancer Epidemiol Biomarkers Prev. 2011 Jul;20(7):1296-302. doi: 10.1158/1055-9965.EPI-11-0250.

11.

Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C.

Lambrecht RW, Sterling RK, Naishadham D, Stoddard AM, Rogers T, Morishima C, Morgan TR, Bonkovsky HL; HALT-C Trial Group.

Gastroenterology. 2011 May;140(5):1490-500.e3. doi: 10.1053/j.gastro.2011.01.053. Epub 2011 Feb 15.

12.

Development and progression of portal hypertensive gastropathy in patients with chronic hepatitis C.

Fontana RJ, Sanyal AJ, Ghany MG, Bonkovsky HL, Morgan TR, Litman HJ, Reid AE, Lee WM, Naishadham D; HALT-C Trial Study Group.

Am J Gastroenterol. 2011 May;106(5):884-93. doi: 10.1038/ajg.2010.456. Epub 2010 Dec 7.

13.

Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C.

Fontana RJ, Dienstag JL, Bonkovsky HL, Sterling RK, Naishadham D, Goodman ZD, Lok AS, Wright EC, Su GL; HALT-C Trial Group.

Gut. 2010 Oct;59(10):1401-9. doi: 10.1136/gut.2010.207423. Epub 2010 Jul 30.

14.

Genetic variations in heme oxygenase-1 and chronic hepatitis.

Bonkovsky HL, Lambrecht RW, Naishadham D.

Hepatology. 2010 Jul;52(1):400-1. doi: 10.1002/hep.23562. No abstract available.

PMID:
20232486
15.

Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C.

Fontana RJ, Sanyal AJ, Ghany MG, Lee WM, Reid AE, Naishadham D, Everson GT, Kahn JA, Di Bisceglie AM, Szabo G, Morgan TR, Everhart JE; HALT-C Trial Group.

Gastroenterology. 2010 Jun;138(7):2321-31, 2331.e1-2. doi: 10.1053/j.gastro.2010.02.058. Epub 2010 Mar 6.

16.

Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial.

Shiffman ML, Morishima C, Dienstag JL, Lindsay KL, Hoefs JC, Lee WM, Wright EC, Naishadham D, Everson GT, Lok AS, Di Bisceglie AM, Bonkovsky HL, Ghany MG; HALT-C Trial Group.

Gastroenterology. 2009 Dec;137(6):1986-94. doi: 10.1053/j.gastro.2009.08.067. Epub 2009 Sep 10. Erratum in: Gastroenterology. 2010 Mar;138(3):1215.

17.

Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial.

Welzel TM, Morgan TR, Bonkovsky HL, Naishadham D, Pfeiffer RM, Wright EC, Hutchinson AA, Crenshaw AT, Bashirova A, Carrington M, Dotrang M, Sterling RK, Lindsay KL, Fontana RJ, Lee WM, Di Bisceglie AM, Ghany MG, Gretch DR, Chanock SJ, Chung RT, O'Brien TR; HALT-C Trial Group.

Hepatology. 2009 Jun;49(6):1847-58. doi: 10.1002/hep.22877.

18.

Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis.

Fontana RJ, Bonkovsky HL, Naishadham D, Dienstag JL, Sterling RK, Lok AS, Su GL; Halt-C Trial Group.

Clin Gastroenterol Hepatol. 2009 Feb;7(2):219-26. doi: 10.1016/j.cgh.2008.10.034. Epub 2008 Nov 7.

19.

DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial.

Morgan TR, Lambrecht RW, Bonkovsky HL, Chung RT, Naishadham D, Sterling RK, Fontana RJ, Lee WM, Ghany MG, Wright EC, O'Brien TR; HALT-C Trial Group.

J Hepatol. 2008 Oct;49(4):548-56. doi: 10.1016/j.jhep.2008.05.011. Epub 2008 Jun 5.

20.

Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C.

Fontana RJ, Goodman ZD, Dienstag JL, Bonkovsky HL, Naishadham D, Sterling RK, Su GL, Ghosh M, Wright EC; HALT-C Trial Group.

Hepatology. 2008 Mar;47(3):789-98. doi: 10.1002/hep.22099.

21.

Social disparities in the burden of occupational exposures: results of a cross-sectional study.

Quinn MM, Sembajwe G, Stoddard AM, Kriebel D, Krieger N, Sorensen G, Hartman C, Naishadham D, Barbeau EM.

Am J Ind Med. 2007 Dec;50(12):861-75.

PMID:
17979135
22.

Work-to-family spillover and fruit and vegetable consumption among construction laborers.

Devine CM, Stoddard AM, Barbeau EM, Naishadham D, Sorensen G.

Am J Health Promot. 2007 Jan-Feb;21(3):175-82.

PMID:
17233235
23.

Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial.

Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, Kahn JA, Lok AS, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Morishima C; HALT-C Trial Group.

Hepatology. 2006 Dec;44(6):1675-84.

24.

Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C.

Bonkovsky HL, Naishadham D, Lambrecht RW, Chung RT, Hoefs JC, Nash SR, Rogers TE, Banner BF, Sterling RK, Donovan JA, Fontana RJ, Di Bisceglie AM, Ghany MG, Morishima C; HALT-C Trial Group.

Gastroenterology. 2006 Nov;131(5):1440-51. Epub 2006 Aug 18.

PMID:
17101320
25.

Issues in design and implementation in an urban birth cohort study: the Syracuse AUDIT project.

Crawford JA, Hargrave TM, Hunt A, Liu CC, Anbar RD, Hall GE, Naishadham D, Czerwinski MH, Webster N, Lane SD, Abraham JL.

J Urban Health. 2006 Jul;83(4):741-59.

26.

Experiences of discrimination: validity and reliability of a self-report measure for population health research on racism and health.

Krieger N, Smith K, Naishadham D, Hartman C, Barbeau EM.

Soc Sci Med. 2005 Oct;61(7):1576-96. Epub 2005 Apr 21.

PMID:
16005789

Supplemental Content

Loading ...
Support Center